Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger - Pharmaceutical Technology

Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb proof-of-concept trials. The newly formed biotech will use the funds to take its eczema bispecific, TALA-125, through to Phase IIb proof-of-concept trials. Talawar Therapeutics and JATT II have merged to create a new biotech focused on progressing assets for immunological disorders. Credit: Anton Vierietin / Shutterstock.com. New Jersey-based biotech, Talawar Therapeutics and JATT II Acquisition have joined forces through a definitive business combination agreement – creating a new biotech that’s aiming to disrupt the crowded atopic dermatitis (AD) market ruled by Sanofi and…

Source: Pharmaceutical Technology